Fractyl Health, Inc.
NGM: GUTSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Fractyl Health, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GUTS Z-Score →About Fractyl Health, Inc.
Healthcare
Biotechnology
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
📊 Fundamental Analysis
Fractyl Health, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -744.2%, which indicates that capital utilization is currently under pressure.
At a current price of $0.46, GUTS currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.38 - $3.03).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$72.98M
Trailing P/E
--
Forward P/E
-0.81
Beta (5Y)
1.19
52W High
$3.03
52W Low
$0.38
Avg Volume
5.44M
Day High
Day Low